Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers, Exosomes & Liquid Biopsy Asia 2019

Andreas Möller's Biography

Andreas Möller, Associate Professor, Group Leader and Head, Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute

Dr. Andreas Möller is Group Leader of the Tumour Microenvironment Laboratory at the QIMR Berghofer Medical Research Institute, Brisbane, Australia. He is also adjunct Associate Professor with the Faculty of Medicine at the University of Queensland, and the School of Biomedical Science at the Queensland University of Technology. Dr Möller received his doctoral training at the German Cancer Research Centre (DKFZ) in Heidelberg, Germany, followed by postdoctoral training at the University of Berne, Switzerland, and the Peter MacCallum Cancer Center, Melbourne, Australia. Dr Möller is an expert in cancer metastasis and cancer immunology, and now has more than 10 years of experience in the Extracellular Vesicle (EV) field. Based on clinical collaborations, patents in the EV field and commercial partners, his work is focused on gaining a better understanding of the role of EVs in cancer progression and their use as cancer biomarkers.

Andreas Möller Image

Protein Content of Extracellular Vesicles as Biomarker in Cancer

Monday, 9 September 2019 at 17:00

Add to Calendar ▼2019-09-09 17:00:002019-09-09 18:00:00Europe/LondonProtein Content of Extracellular Vesicles as Biomarker in CancerCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul,

Despite significant therapeutic advances, cancer remains a leading cause of death worldwide. A significant clinical problem is the generally late discovery of a cancer and the uncertainty of choosing the most effective therapy for the individual patient. Several novel biomarkers are proposed, ranging from genetic and genomic evaluations of the cancer or the cancer material in circulation to assessing nucleic acids, proteins or lipids. Accurate cancer biomarkers, in particular non-invasive liquid biomarkers based on blood samples or other body fluids, will allow clinicians to identify cancer patients early, triage them to the most appropriate intervention and follow the response of the cancer in real time over the course of the therapy.

In this presentation, I will share data on a novel biomarker for Non-Small-Cell Lung Cancer (NSCLC). We have developed a blood-based multi-protein signature capable of accurately prognosticating clinical outcome in NSCLC patient cohorts. This signature is contained in small circulating nano-vesicles termed exosomes. Overall, this work describes a novel prognostic biomarker signature to identify early stage NSCLC patients at risk of developing metastatic NSCLC, thereby enabling implementation of personalized adjuvant treatment decisions.

Add to Calendar ▼2019-09-09 00:00:002019-09-10 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul,